766515-33-7

Basic information

• Product Name: 3-Cyano-2-hydroxy-5-iodopyridine
• Synonyms: 3-Cyano-2-hydroxy-5-iodopyridine;2-Hydroxy-5-iodonicotinonitrile;5-Iodo-2-oxo-1,2-dihydropyridine-3-carbonitrile;1,2-Dihydro-5-iodo-2-oxo-3-pyridinecarbonitrile
• CAS NO: 766515-33-7
• Molecular Formula: C₆H₃IN₂O
• Molecular Weight: 246.01
• Product Categories: alcohol|cyanide| alkyl Iodine
• Mol File: 766515-33-7.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 423.534 °C at 760 mmHg
• Flash Point: 209.946 °C
• Appearance: /
• Density: 2.239 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.724
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 3-Cyano-2-hydroxy-5-iodopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Cyano-2-hydroxy-5-iodopyridine(766515-33-7)
• EPA Substance Registry System: 3-Cyano-2-hydroxy-5-iodopyridine(766515-33-7)

Safety Data

• Hazardous Substances Data: 766515-33-7(Hazardous Substances Data)

Usage

General Description

3-Cyano-2-hydroxy-5-iodopyridine is an organic compound with the chemical formula C6H3IN2O. It is a pyridine derivative that contains a cyano group, a hydroxy group, and an iodine atom. 3-Cyano-2-hydroxy-5-iodopyridine has a molecular weight of 262.99 g/mol and a density of 2.01 g/cm3. It is used in organic synthesis and as a building block in the pharmaceutical industry. Additionally, 3-Cyano-2-hydroxy-5-iodopyridine has been studied for its potential biological activities, including its antimicrobial and antitumor properties.

InChI:InChI=1/C6H3IN2O/c7-5-1-4(2-8)6(10)9-3-5/h1,3H,(H,9,10)

Upstream product

• 20577-27-9 2-hydroxy-3-cyanopyridine 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 

Downstream Products

• 766515-34-8 2-chloro-5-iodopyridine-3-carbonitrile 
• 766515-35-9 1-methyl-3-amino-5-iodo-1H-pyrazolo[3,4-b]pyridine 
• 766515-42-8 1-methyl-3-amino-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-45-1 1-methyl-3-iodo-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-40-6 1-methyl-3-(2,2-dimethyl-propionamido)-5-phenyl-1H-pyrazolo[3,4-b]pyridine 
• 766515-39-3 (E)-1-methyl-3-(2,2-dimethyl-propionamido)-5-styryl-1H-pyrazolo[3,4-b]pyridine 
• 766515-38-2 1-methyl-3-(2,2-dimethyl-propionamido)-5-phenylethynyl-1H-pyrazolo[3,4-b]pyridine 
• 1392150-08-1 5-[(3,5-difluorophenyl)thio]-1H-pyrazolo[3,4-b]pyrazin-3-amine 
• 1392151-65-3 N-(5-(3,5-difluorophenylthio)-1-(4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido) benzoyl)-1H-pyrazolo[3,4-b]pyrazine-3-yl)-4-(4-methylpiperazine-1-yl)-2-(2,2,2-trifluoro-N-(tetrahydro-2H-pyran-4-yl)acetamido)benzamide 
• 1392151-64-2 N-(5-((3,5-difluorophenyl)thio)-1H-pyrazolo[3,4-b]pyrazin-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide 
• 1392151-76-6 1-(5-((3,5-difluorophenyl)thio)-1H-pyrazolo[3,4-b]pyridin-3-yl)-3-(4-(4-methylpiperazin-1-yl)phenyl)thiourea 
• 1392151-89-1 5-(3,5-difluorophenyl sulfinyl)-1H-pyrazolo[3,4-b]pyrazin-3-amine 
• 1392151-92-6 5-[(3,5-difluorophenyl)sulfonyl]-1H-pyrazolo[3,4-b]pyrazin-3-amine 

Relevant articles and documents

Original synthesis of radiolabeling precursors for batch and on resin one-step/late-stage radiofluorination of peptides

Radiolabeling of peptides with fluorine-18 is hurdled by their chemical sensitivity and complicated processes. Original triflyl-pyridine intermediates afforded ammonium precursors that were radiolabeled at low temperature. From that study, a generic tag h

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.